Austar Lifesciences Limited provided earnings guidance for the six months ended 30 June 2022. The Group is expected to record a profit attributable to the owners of the Company of not less than RMB 43 million for the six months ended 30 June 2022, as compared to the profit attributable to the owners of the Company of approximately RMB 218 million for the six months ended 30 June 2021.